Reviva Pharmaceuticals Holdings Inc. Warrants (25/12/2025) RVPHW 深 滬
已收盤 12-12 16:00:00 美东时间
0.003
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.003
- 總市值 2.77万
- 52周最高 0.3678
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.003
- 委 比 0.00%
- 總股本 923.17万
- 歷史最高 3.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.003
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Delisting of Securities from The Nasdaq Stock Market
The Nasdaq Stock Market announced the delisting of several companies' securities, including CERo Therapeutics Holdings, Inc., Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co., Ltd., Captivision Inc., Actelis Networks, Inc., American Rebel Holdings, Inc., Reviva Pharmaceuticals Holdings, Inc., Alchemy Investments Acquisition Corp 1, Bitcoin Depot Inc., Inotiv, Inc., GoHealth, Inc., Functio...
07-10 16:00
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
Reviva Pharmaceuticals Holdings, Inc. announced that its CEO, Laxminarayan Bhat, PhD, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026, from 2:40-3:00 PM ET. Investors can register and view the chat [here](https://www.globenewswire.com/Tracker?data=ZQ4QHba1Md3if_7dhLdM9sszgHH-KoFFIMzCc1ePqROgxr4lyJ_Yi1ukhjpyE4vSGuyaAKmi0kpuBvajVRQAuYoK1XTKns0tyHpbsZbxjcyO-X0...
05-18 12:00
Reviva Pharmaceuticals Q1 EPS $(0.46) Beats $(0.62) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.62) by 25.81 percent. This is a 82.31 percent increase over losses of $(2.60) per share
05-14 04:39
Reviva Pharmaceuticals To Be Delisted From Nasdaq On May 14
As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the "Company") was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") to maintain
05-13 20:28
Reviva Updates Brilaroxazine Strategy and Funding Outlook
Reviva Pharmaceuticals Holdings ( ($RVPH) ) just unveiled an announcement. On A...
04-15 20:28
Reviva Pharmaceuticals Holdings Says Aims To Extend Brilaroxazine Patent Life And Exclusivity Potentially Through 2046; To Initiate Trial Activities In Q2 2026, Begin Enrollment In Q3 2026, For RECOVER-2; Preparing To Seek FDA Alignment On New Form Of Brilaroxazine For NDA
Regulation FD Disclosure.On April 15, 2026, Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") issued a letter to shareholders announcing certain business updates, including in connection with the
04-15 20:16
Maxim Group Downgrades Reviva Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
04-08 21:20
